Left Atrial Appendage Transcatheter Occlusion with AMPLATZER™ Amulet™ Device: Real Life Data with Mid-Term Follow-Up Results

Conclusion: We concluded that LAA occlusion using the Amulet ™ LAA occluder can be performed with high procedural success and acceptable outcomes.Resumo Fundamento: A oclus ão do apêndice atrial esquerdo (AAE) é uma terapia alternativa para pacientes com fibrilação atrial que tenham alto risco embólico e contraindicações à terapia anticoagulante. Objetivo: Avaliar a viabilidade, segurança e resultados de médio prazo da oclusão percutânea do AAE, incluindo a trombose relacionada à prótese. Métodos: Sessenta pacientes consecutivos que foram submetidos à oclusão percutânea do AAE com a prótese AMPLATZER ™ Amulet ™ de setembro de 2015 a mar ço de 2018 foram incluídos no estudo. Os pacientes foram acompanhados por 21 ± 15 meses (mediana - 20 meses, intervalo interquartílico - 9 a 27 meses). A avaliação pós-procedimento foi feita no 1º, 6º e 12º mês. Os pacientes foram examinados clinicamente e um ecocardiograma transesofágic o foi realizado a cada visita. A condição de normalidade das variáveis foi avaliada por meio do teste de Kolmogorov-Smirnov. Os valores de p3 mm) na avalia ção do 1º mês, que desapareceu no 12º mês de seguimento. Conclusão: Concluiu-se que a oclusão do AAE com o ...
Source: Arquivos Brasileiros de Cardiologia - Category: Cardiology Source Type: research

Related Links:

Conclusions: A substantial portion of hospitalized AF patients did not receive any AC therapy, particularly those patients with an AF diagnosis in the second position on hospital records. The predictors of inpatient AC treatment that were identified may be helpful in the clinical decision-making process for patients who are hospitalized with AF. PMID: 33021129 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
CONCLUSION:  During the open-label extension, annual rates of stroke or systemic embolism, hemorrhagic stroke, and major bleeding remained as low as those observed during apixaban treatment in AVERROES. These data support the long-term efficacy and safety of apixaban in patients with atrial fibrillation. PMID: 33011964 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Thromb Haemost Source Type: research
CONCLUSIONS: In highly selected patients at very HBR, discontinuation of any antithrombotic therapy after LAAC appears safe and feasible. PMID: 32999093 [PubMed - in process]
Source: The Journal of Invasive Cardiology - Category: Cardiology Tags: J Invasive Cardiol Source Type: research
CONCLUSIONS: Long-term incidence of thromboembolism was extremely low in patients with AF treated with CA, while that of major bleeding was not especially low. Clinical Trials Registry: UMIN000032829 / UMIN000032830. PMID: 33011056 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - Category: Cardiology Authors: Tags: J Cardiol Source Type: research
ConclusionsPercutaneous LAAO procedures can be safely performed by cardiac surgeons, with no cardiological assistance. LAAO done by surgeons is safe and effective, and periprocedural and long ‐term outcomes are excellent. Cardiac surgeons should be trained in both types of LAAO: endocardial and epicardial.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsConcurrent LAA exclusion during MVR is a safe and effective way to reduce postoperative ischemic stroke, particularly in patients with AF.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Kawabata M, Goya M, Maeda S, Yagishita A, Takahashi Y, Sasano T, Hirao K Abstract There is little data on management and outcomes of atrial fibrillation (AF) patients on direct oral anticoagulants (DOAC) undergoing general surgery.We retrospectively assessed 98 surgeries in 85 nonvalvular AF patients aged 73 ± 8 (59 men) receiving DOACs. Cardiac, emergency, and minimally invasive surgeries were excluded.The CHA2DS2-VASc score ranged from 0 to 8. The DOACs being given were: dabigatran, 16; rivaroxaban, 25; apixaban, 28; and edoxaban, 16. While the DOACs were not suspended in 11 cases, they were inter...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Abstract BACKGROUND:  The effects of anticoagulants at extremes of body weight (BW) are not well described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics and clinical outcomes in patients randomized to warfarin, higher dose edoxaban (HDER), and lower dose edoxaban (LDER) regimens at extremes of BW in ENGAGE AF-TIMI 48. METHODS AND RESULTS:  We analyzed three BW groups: low BW (LBW: 95th percentile, ≥120 kg, N = 1,093). In the warfarin arm, LBW patients had higher rates of stroke/systemic embolism (SSE: 6.5 vs. 4.7 in MBW vs. 1.6% in HBW, P trend 
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Thromb Haemost Source Type: research
The incidence of stroke during TAVI up to 5 % (minimum ). Stroke risk reduction during TAVI is a critical requirement that can be a deterrent against this wonderful Intervention. Many devices are being considered EmbolX (Edwards life science) Emrella Sentinel (Claret medical) TriGaurd (Keystone)   TriGaurd 3just got the approval from CE and appear promising. (REFLECT trial) It is inserted through the transfemoral route , deflects embolic material to descending aorta since it covers all the three branches of Arch.What happens to these deflected particles? Any bodys guess. So , in my understanding it conve...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: tavr tavi Uncategorized embolic protective device for tavi tavr embolx sentinel. triguard 3 Source Type: blogs
AbstractPurpose of ReviewIn patients with atrial fibrillation who are unable to take novel oral anticoagulants for stroke prophylaxis due to bleeding risk or other contraindications, left atrial appendage (LAA) occlusion and exclusion devices have shown benefit. In this review, we highlight the risks and benefits associated with LAA removal.Recent FindingsLAA, once considered a vestigial organ, has been shown to have physiological, anatomical, and arrhythmogenic properties. Device-related complications such as pericardial effusion, device embolization, device-related thrombus, while uncommon, are still present. With increa...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
More News: Alternative and Complementary Therapies | Atrial Fibrillation | Bleeding | Cardiology | Heart | Statistics | Thrombosis